What Happened
The FDA's proposed "Interim Access Policy for Compounding Using Certain Peptides" reached the White House Office of Information and Regulatory Affairs (OIRA) on October 14, 2026, where it is listed as pending review. The filing confirms that a policy exists. It does not disclose the text, the substances covered, or the conditions pharmacies would have to satisfy.
The submission follows the July 23-24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee, which took up BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and Epitalon-related bulk drug substances for possible inclusion on the Section 503A bulks list. Those recommendations are advisory; they do not amend the list.
Reporting around the proposal describes temporary enforcement discretion rather than a rule change. Pharmacies meeting conditions such as state licensure, a valid prescription, enhanced patient disclosures and serious adverse event reporting could dispense certain peptides while FDA evaluates a permanent framework. FDA career staff have reportedly opposed the approach on patient-safety and drug-approval grounds. On November 2, trade-press commentary argued that a permissive peptide policy would weaken the incentive to run controlled trials and expose patients to molecules with thin human safety data.
Who Is Affected
- Compounding pharmacies and 503B outsourcing facilities deciding whether to build or expand peptide services before the text is public.
- Telehealth prescribers and clinics whose menus depend on compounded peptides.
- Direct-to-consumer sellers using "research use only" labels. FDA has relied on website marketing in warning letters, so the disclaimer is not a reliable shield.
- Patients buying unapproved peptides online without lot-level testing.
- Trial sponsors working with the same molecules, who now face a market where unapproved versions may be easier to obtain than the evidence base justifies.
Timeline
- September 2023 - FDA places several peptides in Category 2, citing immunogenicity risk, peptide-related impurities and gaps in API characterization.
- July 23-24, 2026 - The advisory committee reviews seven peptide substances for the 503A bulks list.
- October 14, 2026 - The interim access policy is submitted to OIRA for executive review.
- November 2, 2026 - Public criticism of the direction sharpens.
- Next - OIRA clearance, then issuance. No legal deadline is attached, and the terms may narrow before publication.
What This Means for Researchers
Nothing in the current record legalizes compounding of these substances. An advisory vote is not a bulks-list amendment, and a policy under review is not an issued policy. Researchers should treat the covered-substance list, route restrictions and reporting duties as unknown until the text is published, and should plan for the possibility that the framework is time-limited or withdrawn.
How to Verify Your Peptides
Regardless of how the policy lands, the analytical questions stay the same: identity, purity and fill weight. Our guides explain how peptide testing works and what HPLC and mass spectrometry can and cannot prove, and the testing FAQ covers how to read a certificate of analysis. Any supplier claiming a peptide is "FDA approved" because of this policy is wrong on its face - FDA does not approve compounded drugs.
Safe Alternatives
Where access tightens, researchers can compare documented compounds in our peptide directory - including BPC-157, TB-500 and Semax - and review sourcing and testing records in our vendor directory. PepsReview will publish the policy's actual terms when they are released.
Sources
Industry reports; regulatory announcements; OIRA review docket; FDA advisory committee materials; trade-press commentary.